June 11, 2020
New treatment guides and recommendations of Danish Medicines Council
In April and May 2020, Danish Medicines Council (Medicinrådet) issued two new treatment guides (on metastatic kidney cancer and ovarian cancer), two recommendations (on cemiplimab and voretigene neparvovec) and two drug recommendations (on antimycotics and HIV)

Medicines Council makes recommendations on what new medicines should be the standard treatments in the country's hospitals. The Council assesses whether there is a reasonable relationship between the clinical value of the drug and the cost of treatment with the drug

On April 27, 2020, Medicines Council issued a treatment guide on BRCA-mutated ovarian, ovarian, or primary abdominal cancer drugs. It provides dosing, priority, and conditions of use for Olaparib, Niraparib, or Bevacizumab in different clinical situations.

On May 13, 2020, Medicines Council published a treatment guide with drug recommendations on Metastatic kidney cancer. It recommends pembrolizumab/axitinib and avelumab/axitinib as the first-line to treat 80% of patients in a good prognostic group. Tivozanib, pazopanib, and sunitinib can be equated alternatively to patients in the good prognostic group that cannot tolerate first-line therapy. For patients in an intermediate/poor prognostic group, nivolumab/ipilimumab is recommended as the first-line therapy in 80% of cases, while avelumab/axitinib and pembrolizumab/axitinib should not be used routinely.

Cemiplimab (Libtayo) was recommended as a standard treatment for locally advanced and metastatic squamous cell carcinomas Link. The Council assesses that there is a reasonable clinical value/cost relationship for cemiplimab treatment.

Medicines Council recommends voretigene neparvovec (Luxturna) as a possible standard treatment for patients with hereditary RPE65-related retinal dystrophy Link. The price was estimated as unreasonably high. However, the new payment agreement lowers it significantly.

Also, the following drug recommendations were approved: for antimycotics and for HIV.

See the full details in Danish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)